Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 14 September

Sophia Mavridis
September 14, 2021

Morning Bell 13 September

Jessica Amir
September 13, 2021

Weekly Wrap 10 September

Jessica Amir
September 10, 2021

Morning Bell 10 September

Sophia Mavridis
September 10, 2021

Morning Bell 9 September

Paulina Peters
September 9, 2021

Morning Bell 8 September

Jessica Amir
September 8, 2021

Morning Bell 7 September

Jessica Amir
September 7, 2021

Morning Bell 6 September

Jessica Amir
September 6, 2021

Weekly Wrap 3 September

Jessica Amir
September 3, 2021

Morning Bell 3 September

Sophia Mavridis
September 3, 2021

Morning Bell 2 September

Paulina Peters
September 2, 2021